Versant Ventures and OrbiMed led a $65m in Series A round in Helicore Biopharma.

Versant Ventures, a venture capital firm, and OrbiMed, a private equity firm, led a $65m in Series A round in Helicore Biopharma, a biopharmaceutical company, with participation from Longitude Capital and Wellington Management. "Recent scientific advances have fundamentally changed our understanding of obesity and the conditions associated with it. Current treatments, though impactful, often fall short of addressing the complex, long-term needs of patients. By targeting GIP directly, we’ve rapidly advanced a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability, and convenient dosing regimens," Gerrit Klaerner, Helicore President and CEO.